It’s Here: CCO’s Official Conference Coverage of AASLD 2014‏

Official Conference Coverage of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases

Capsule Summaries
Reviews by expert faculty on key studies highlighted at the conference
Downloadable slides
Review Conference Coverage

Ledipasvir/Sofosbuvir Regimens Highly Effective, Safe, and Well Tolerated in Patients With Genotype 1 HCV and Compensated Cirrhosis
Similar SVR12 rates with 24-week ribavirin-free regimen vs 12-week ribavirin-containing regimen in treatment-experienced cirrhotics.
Review the Full Capsule

HCV-TARGET: Real-World Use of Sofosbuvir-Containing Regimens Yields Overall SVR4 Rates ≥ 85% in Patients With Genotype 1 or 2 HCV Infection
To date, regimens allowing removal of peginterferon most commonly selected: sofosbuvir plus ribavirin in patients with genotype 2/3 infection and sofosbuvir plus simeprevir with or without ribavirin in genotype 1 HCV infection.
Review the Full Capsule

ELECTRON-2: High SVR12 Rates With Sofosbuvir + NS5A Inhibitor GS-5816 With or Without Ribavirin in Treatment-Naive, Noncirrhotic Genotype 3 HCV-Infected Patients in Phase II Trial
Low levels of discontinuation due to adverse events; no virologic failure with 100-mg dose of GS-5816. Inclusion of ribavirin associated with more frequent adverse events with no efficacy benefit.
Review the Full Capsule

ALLY-3: High SVR12 Rates With 12 Weeks of Daclatasvir + Sofosbuvir in Treatment-Naive or Treatment-Experienced Patients With Genotype 3 HCV Infection
SVR12 rates substantially lower for both treatment-naive and treatment-experienced cirrhotics vs noncirrhotics.
Review the Full Capsule

Final C-WORTHY Results: Grazoprevir + Elbasvir ± RBV Yields High SVR12 Rates in Genotype 1 Treatment-Naive Cirrhotic Patients and Previous Null Responders
SVR12 rates ≥ 90% were attained regardless of RBV use or treatment duration.
Review the Full Capsule